Donepezil: An anticholinesterase inhibitor for Alzheimer's disease

American Journal of Health-System Pharmacy

Volumn 54, Issue 24, 1997, Pages 2805-2810

  Shintani, Ellen Y ^a  

^a University HealthSystem Consortium   (United States)

Author keywords

Alzheimer's disease; Dementia; Donepezil hydrochloride; Dosage; Drug interactions; Parasympathomimetic agents; Pharmacokinetics; Toxicity

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

AGED; ALZHEIMER DISEASE; ANOREXIA; CHEMICALLY INDUCED DISORDER; DIARRHEA; DRUG ADMINISTRATION; DRUG INTERACTION; ECONOMICS; HUMAN; NAUSEA; REVIEW;

AGED; ALZHEIMER DISEASE; ANOREXIA; CHOLINESTERASE INHIBITORS; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HUMANS; INDANS; NAUSEA; PIPERIDINES;

EID: 0031573619     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/54.24.2805     Document Type: Article

References (27)

1. Jorm AF, Körten AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand. 1987; 76:465-79.
2. Cummings JL, Benson BF. Dementia: a clinical approach. 2nd ed. Boston: Butterworth-Heineman; 1992.
3. Roth ME. Advances in Alzheimer's disease: a review for the family physician. / Fam Pract. 1993; 37:593-607.
4. Evans DA, Funkstein HH, Albert MS et al. Prevalence of Alzheimer's disease in a community of older persons: higher than previously reported. JAMA. 1989; 262:2551-6.
5. Gooch MD, Stennett DJ. Molecular basis of Alzheimer's disease. Am J Heatth-Syst Pharm. 1996; 53:1545-57.
6. Becker RE. Therapy of the cognitive deficit in Alzheimer's disease: the cholinergic system. In: Becker R, Giacobini E, eds. Cholinergic basis for Alzheimer therapy. Boston: Birkhauser; 1991:1-22.
7. Stern Y, Sano M, Mayeux R. Long-term administration of oral physostigmine in Alzheimer's disease. Neurology. 1988; 38:1837-41.
8. Thal LJ, Masur DM, Blau AD et al. Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease. / Am GeriatrSoc. 1989; 37:42-8.
9. Knapp MJ, Knopman DS, Solomon PR et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA. 1994; 271:985-91.
10. Rogers SL, Yamanishi Y, Yamatsu K. E2020: the pharmacology of a piperidine cholinesterase inhibitor. In: Becker R, Giacobini E, eds. Cholinergic basis for Alzheimer therapy. Boston: Birkhauser; 1991:315-20.
11. Sherman KA. Pharmacodynamics of oral E2020 and tacrine in humans: novel approaches. In: Becker R, Giacobini E, eds, Cholinergic basis for Alzheimer therapy. Boston: Birkhauser; 1991:321-8.
12. Mihara M, Ohnishi A, Tomono Y et al. Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. Intf Clin Pharmacol. 1993; 31:223-9.
13. Ohnishi A, Mihara M, Kamakura H et al. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. / Clin Pharmacol. 1993; 33:1086-91.
14. Aricept package insert. New York, NY: Roerig, Division of Pfizer, Inc.; 1996.
15. Rogers SL, Walters EJ, Freidhoff LT. The pharmacokinetics (PK) and pharmacodynamics (PD) of E2020 (R,S)-l-benzyl-4-[(5,6dimethoxy-l-indanon)-2-yl]methylpiperdine hydrochloride, a novel inhibitor of acetylcholinesterase (AChE): implications for use in the treatment of Alzheimer's disease. Neurobiol Aging. 1992; 13:462. .
16. Rogers SL, Friedhoff LT and the Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia. 1996; 7:293-303.
17. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am ] Psychiatry. 1984; 141:1356-64.
18. Guy W. ECDEU assessment manual for psychopharmacology. Rockville, MD: National Institute of Mental Health; 1976; publication no. 76-388.
19. Donaldson SW, Wagner CC, Gresham GE. A unified ADL evaluation form. Arch Phys Med Rehabil. 1973; 54:175-80.
20. Berg L, Miller JP, Baty J et al. Mild senile dementia of the Alzheimer type: evaluation of intervention. Ann Neural. 1992; 31:242-9.
21. Rogers SL, Perdomo C, Friedhoff LT. Clinical benefits are maintained during long-term treatment of Alzheimer's disease with the acetylcholinesterase inhibitor, E2020. Proceedings of the 8th European College of Neuropsychopharmacology. Venice, Italy; 1995. .
22. Stern RG, Mohs RC, Davidson M et al. A longitudinal study of Alzheimer's disease measurement, rate and predictors of cognitive deterioration. Am I Psychiatry. 1994; 151:390-6.
23. Ph'zer/Eisai. Aricept is "approvable" for Alzheimer's disease symptoms; tenidap for rheumatoid arthritis dropped by Pfizer following "not approvable" letter. FDC Rep. 1996; 58(Sep 30):9.
24. Rogers SL, Doody R, Mohs R et al. E2020 produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: results of a 30-week phase III trial. Neurology. 1996; 46:A217.
25. Kaufer DI, Cummings JL, Christine D. Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study./ Geriatr Psychiatry Neural. 1996; 9(l):l-6.
26. Knopman D. Long term tacrine treatment: effects on nursing home replacement and mortality. Neurology. 1996; 47:166-77.
27. Lübeck DP, Mazonson PD, Bowe T. Potential effect of tacrine on expenditures for Alzheimer's disease. Med Interface. 1994; 7(10):130-8.